Tenosynovial Giant Cell Tumors (TSGCTs)—Market Insights, Epidemiology and Market Forecast-2028

Tenosynovial Giant Cell Tumors (TSGCTs)Market Insights, Epidemiology and Market Forecast2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Tenosynovial Giant Cell Tumors (TSGCTs) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Tenosynovial Giant Cell Tumors (TSGCTs) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 20172028
Tenosynovial Giant Cell Tumors (TSGCTs) - Disease Understanding and Treatment Algorithm
Tenosynovial giant cell tumors (TGCT) are a group of neoplastic disorders that involve synovium-lined tendon sheaths, synovial joints, and adjacent soft tissue. They are divided on the basis of their localization and diffuse subtypes. These cell tumor is abnormal growth of tissue derived from the synovium that causes activation of immune cells, specifically macrophages, leading to formation of a mass. These tumors are often classified by their growth pattern (localized or diffused) and location (intra- or extra-articular). Tenosynovial giant cell tumor is the term used in 2013 by the World Health Organization classification. They have previously been known as giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumor of the tendon sheath (PVNTS), extra-articular pigmented villonodular tumor of the tendon sheath or localized or focal nodular synovitis. Tenosynovial giant cell tumors (TGCTs) are locally aggressive, soft tissue lesions characterized by inflammation of the synovial lining among joints and tendons. These neoplasms are thought to arise via overexpression of the colony-stimulating factor 1 receptor.
It is important to differentiate tumor and its type for the better treatment option and for the optimized results. The major diagnosis options are limited and the basic radiographic features are the main point of differentiation for the tenosynovial giant cell tumor. The initiation of the diagnosis is done only with the plain radiograph and tumor is differentiated when masses arise from tendons, commonly of the hand, as they may cause pressure erosions on the underlying bone. The diagnosis is done to estimate the type size and affected area of the tumor. It is known that tenosynovial giant cell tumors are clonal neoplastic tumors driven by overexpression of CSF1. The diagnosis is done to differentiate the tumor being cancerous or giant cell tumor. Tenosynovial giant cell tumor (TSGCT) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. The various diagnosis techniques involve imaging features (radiography, MRI, computed tomography, ultrasonography, clinical testing, workup, and biopsy).
The DelveInsight Tenosynovial Giant Cell Tumors (TSGCTs) market report gives the thorough understanding of Tenosynovial Giant Cell Tumors (TSGCTs) by including details such as disease introduction, clinical features, classification, etiology, pathogenesis, biomarkers and diagnosis.
Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology
According to the National Organization for Rare Disorders (NORD), the incidence of Tenosynovial Giant Cell Tumor (TSGCTs) is estimated to be 1.8 people per one million people in the general population based on a study conducted in the United States in 1980. Tenosynovial giant cell tumors mainly affect individuals between 25 and 40 years of age, with a median age of diagnosis of 30. However, these tumors can affect the elderly and younger children as well.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Tenosynovial Giant Cell Tumors (TSGCTs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 20172028 for the following aspects:
The disease epidemiology covered in the report is segmented by:
Diagnosed Incidence of Tenosynovial Giant Cell Tumors (TSGCTs)
Growth Pattern-specific Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs)
Gender-specific Diagnosed Incidence of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs)
Gender-specific Diagnosed Incidence of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
Tumor Localization of Localized Tenosynovial Giant Cell Tumor (L-TSGCTs)
Tumor Localization of Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs)
A study conducted by David et al. titled Tenosynovial Giant Cell Tumor: Case Report and Review stated that Pigmented Villonodular Synovitis is rare, with an estimated annual incidence of 1.8 patients per million. It usually affects young adults (average age, 35 years) but has a wide age range and is slightly more common in women. It usually affects large joints, especially the knee, which accounts for 7580% of cases. The hip is the second most common site approximately 15%. It is treated with wide, local excision and total synovectomy or arthroplasty; it has a high local recurrence rate, up to 50%, often with multiple recurrences. Diffuse-type GCT is locally aggressive and recurs in 3350% of cases, often with multiple recurrences. Giant cell tumor of tendon sheath is generally indolent and is successfully treated by simple excision. However, it recurs approximately 25% of the time.
The incidence rate reveals its rarity for localized type (excluding digits), 10.2 per million person-years and for diffuse-type, and 4.1 per million person-years. TGCT is a monoarticular disease, concerning large joints, typically about the knee, 46% in localized-type and 6475% in diffuse-type. The male-female ratio is about 1:1.5 for both types, with a median age at the time of TGCT diagnosis of 3050 years. After surgical resection, high recurrence rates are known, with the localized type up to 50% and the diffuse-type up to 92% was figured out in a study titled The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life conducted by Mastboom et al.
?
Tenosynovial Giant Cell Tumors (TSGCTs) Drug Chapters
This segment of the Tenosynovial Giant Cell Tumors (TSGCTs) report encloses the detailed analysis of late stage (Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of Tenosynovial Giant Cell Tumors (TSGCTs) and awareness of the disease. The overall dynamics of Tenosynovial Giant Cell Tumors (TSGCTs) market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Five Prime Therapeutics, Novartis, and others will significantly increase the market during the forecast period (20192028).
Tenosynovial Giant Cell Tumors (TSGCTs) Market Outlook
Tenosynovial giant cell tumors (TGCT), also known as Pigmented Villonodular Synovitis (PVNS), is a rare disease that arises from the synovium, bursae, and tendon sheaths of young adults between 20 and 40 years of age. Origination and history of trauma remain controversial. TGCT is classified as a localized type or diffuse type according to the extent of synovial involvement and the location. The diffuse type (D-TGCT) usually affects larger joints, is often intra-articular, infiltrative, affecting the entire synovium, and has more aggressive behavior.
The treatment for Tenosynovial Giant Cell Tumors (TSGCTs) majorly includes surgery, which is the main treatment option, but the tumor generally recurs, particularly in pigmented villonodular synovitis, which is the diffuse-type of giant cell tumor. If it remains untreated or if the tumor continually recurs, these tumors can result in damage and degeneration of the affected joint and surrounding tissues or structures. Sometimes, they can cause significant disability. After surgical methods, systemic therapy in the context of a nonlethal tumor can be employed to reduce surgical morbidity and to preserve function and patients quality of life. Because TGCT is associated with characteristic cytogenetic abnormalities resulting in the overexpression of CSF1, systemic therapies targeting the CSF1/CSF1R axis like imatinib, nilotinib, and others have been tested in patients with locally advanced or relapsed DTGCT.
The treatment of TSGCTs mainly follows a mainstay treatment, i.e., surgery followed by other alternatives, such as Radiation Therapy, Radiosynovectomy, and Systemic Therapies (CSF1 inhibitors and Tyrosine Kinase Inhibitors).
This segment gives a through detail of market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criterias, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Tenosynovial Giant Cell Tumors (TSGCTs) in the 7MM is expected to change from 20192028.
Tenosynovial Giant Cell Tumors (TSGCTs) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 20172028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Tenosynovial Giant Cell Tumors (TSGCTs) such as Cabiralizumab (Five Prime Therapeutics), Nilotinib (Novartis), and other targeted therapies in the forecast period [20192028] will also create a positive impact on the Tenosynovial Giant Cell Tumors (TSGCTs) market.
Tenosynovial Giant Cell Tumors (TSGCTs) Report Insights
Patient Population
Therapeutic Approaches
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies
Tenosynovial Giant Cell Tumors (TSGCTs) Report Key Strengths
10-Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition
Tenosynovial Giant Cell Tumors (TSGCTs) Report Assessment
Current Treatment Practices
Unmet Needs
Market Attractiveness
Market Drivers and Barriers

Key Benefits
This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Tenosynovial Giant Cell Tumors (TSGCTs) market
Organize sales and marketing efforts by identifying the best opportunities for Tenosynovial Giant Cell Tumors (TSGCTs) market
To understand the future market competition in the Tenosynovial Giant Cell Tumors (TSGCTs) market.

List Of Tables

Table 1: Localization of ALNS in the different regions of the knee joint.
Table 2: Classification and Nomenclature of Tenosynovial Giant Cell Tumors (TSGCTs)
Table 3: Tenosynovial Giant Cell Tumors (TSGCTs) Total Diagnosed Incident Population in the 7MM (20172028)
Table 4: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United States (20172028)
Table 5: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United States (20172028)
Table 6: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United States (20172028)
Table 7: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United States (20172028)
Table 8: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United States (20172028)
Table 9: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United States (20172028)
Table 10: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Germany (20172028)
Table 11: Total Cases of Locally Advanced/Metastatic Tenosynovial Giant Cell Tumors (TSGCTs) in Germany (20172028)
Table 12: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Germany (20172028)
Table 13: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Germany (20172028)
Table 14: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Germany (20172028)
Table 15: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Germany (20172028)
Table 16: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in France (20172028)
Table 17: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in France (20172028)
Table 18: Tenosynovial Giant Cell Tumors (TSGCTs) Severity-specific Diagnosed Incident Population in France (20172028)
Table 19: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in France (20172028)
Table 20: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in France (20172028)
Table 21: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in France (20172028)
Table 22: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Italy (20172028)
Table 23: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Italy (20172028)
Table 24: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Italy (20172028)
Table 25: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Italy (20172028)
Table 26: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Italy (20172028)
Table 27: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Italy (20172028)
Table 28: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Spain (20172028)
Table 29: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Spain (20172028)
Table 30: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Spain (20172028)
Table 31: Diffuse Tenosynovial Giant Cell Tumors (TSGCTs) Gender-specific Diagnosed Incidence in Spain (20172028)
Table 32: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Spain (20172028)
Table 33: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Spain (20172028)
Table 34: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United Kingdom (20172028)
Table 35: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United Kingdom (20172028)
Table 36: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (20172028)
Table 37: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (20172028)
Table 38: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United Kingdom (20172028)
Table 39: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United Kingdom (20172028)
Table 40: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Japan (20172028)
Table 41: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Japan (20172028)
Table 42: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Japan (20172028)
Table 43: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Japan (20172028)
Table 44: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Japan (20172028)
Table 45: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Japan (20172028)
Table 46: Comparison of Emerging Drugs Under Development
Table 47: Cabiralizumab, Clinical Trial Description
Table 48: Nilotinib, Clinical Trial Description
Table 49: DCC-3014, Clinical Trial Description
Table 50: Lacnotuzumab, Clinical Trial Description
Table 51: 7 Major Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in USD Million (20172028)
Table 52: United States Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 53: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in the US, in USD Million (20172028)
Table 54: Germany Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 55: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Germany, in USD Million (20172028)
Table 56: France Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 57: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in France, in USD Million (20172028)
Table 58: Italy Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 59: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Italy, in USD Million (20172028)
Table 60: Spain Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 61: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Spain, in USD Million (20172028)
Table 62: United Kingdom Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 63: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in the UK, in USD Million (20172028)
Table 64: Japan Market Size of Tenosynovial Giant Cell Tumors (TSGCTs), USD Million (20172028)
Table 65: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Japan, in USD Million (20172028)

List Of Figures

Figure 1: Illustration shows a giant cell tumor at the lower end of the thighbone and is formed by the fusion of several cells, giant cells show multiple nuclei when viewed under a microscope.
Figure 2: Localization of ALNS (articular Localized Pigmented Villonodular) form in the different regions of the knee joint.
Figure 3: Molecular pathogenesis of tenosynovial giant cell tumor/pigmented villonodular synovitis.
Figure 4: Classification of Tenosynovial GCTs
Figure 5: Classification of tenosynovial GCTs. GCT, giant cell tumor; PVNS, pigmented villonodular synovitis
Figure 6: Tenosynovial Giant Cell Tumors (TSGCTs) Total Diagnosed Incident Patient Population in the 7MM (20172028)
Figure 7: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United States (20172028)
Figure 8: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United States (20172028)
Figure 9: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United States (20172028)
Figure 10: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United States (20172028)
Figure 11: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United States (20172028)
Figure 12: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United States (20172028)
Figure 13: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Germany (20172028)
Figure 14: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Germany (20172028)
Figure 15: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Germany (20172028)
Figure 16: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Germany (20172028)
Figure 17: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Germany (20172028)
Figure 18: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Germany (20172028)
Figure 19: Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs) in France (20172028)
Figure 20: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in France (20172028)
Figure 21: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in France (20172028)
Figure 22: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in France (20172028)
Figure 23: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in France (20172028)
Figure 24: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in France (20172028)
Figure 25: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Italy (20172028)
Figure 26: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Italy (20172028)
Figure 27: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Italy (20172028)
Figure 28: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Italy (20172028)
Figure 29: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Italy (20172028)
Figure 30: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Italy (20172028)
Figure 31: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in Spain (20172028)
Figure 32: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Spain (20172028)
Figure 33: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Spain (20172028)
Figure 34: Diffuse Tenosynovial Giant Cell Tumors (TSGCTs) Gender-specific Diagnosed Incidence in Spain (20172028)
Figure 35: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Spain (20172028)
Figure 36: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Spain (20172028)
Figure 37: Tenosynovial Giant Cell Tumor (TSGCTs) Diagnosed Incidence in the United Kingdom (20172028)
Figure 38: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in the United Kingdom (20172028)
Figure 39: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (20172028)
Figure 40: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in the United Kingdom (20172028)
Figure 41: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in the United Kingdom (20172028)
Figure 42: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in the United Kingdom (20172028)
Figure 43: Diagnosed Incidence of Tenosynovial Giant Cell Tumor (TSGCTs) in Japan (20172028)
Figure 44: Tenosynovial Giant Cell Tumor (TSGCTs) Growth Pattern-specific Diagnosed Incidence in Japan (20172028)
Figure 45: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Gender-specific Diagnosed Incidence in Japan (20172028)
Figure 46: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Gender-specific Diagnosed Incidence in Japan (20172028)
Figure 47: Localized Tenosynovial Giant Cell Tumor (L-TSGCTs) Tumor Localization in Japan (20172028)
Figure 48: Diffuse Tenosynovial Giant Cell Tumor (D-TSGCTs) Tumor Localization in Japan (20172028)
Figure 49: Effects of Imatinib on components of the anticancer immunosurveillance system.
Figure 50: Mechanism of Pexidartinib on the giant tumor cells
Figure 51: Treatment algorithm for Tenosynovial Giant Cell Tumors
Figure 52: Unmet Needs of Tenosynovial giant cell tumor
Figure 53: 7 Major Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in USD Million (20172028)
Figure 54: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in the United States, USD Millions (20172028)
Figure 55: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in the US, in USD Million (20172028)
Figure 56: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in Germany, USD Millions (20172028)
Figure 57: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies, in Germany, in USD Million (20172028)
Figure 58: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in France, USD Millions (20172028)
Figure 59: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in France, in USD Million (20172028)
Figure 60: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in Italy, USD Millions (20172028)
Figure 61: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Italy, in USD Million (20172028)
Figure 62: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in Spain, USD Millions (20172028)
Figure 63: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Spain, in USD Million (20172028)
Figure 64: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in the United Kingdom, USD Millions (20172028)
Figure 65: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in the United Kingdom, in USD Million (20172028)
Figure 66: Market Size of Tenosynovial Giant Cell Tumors (TSGCTs) in Japan, USD Millions (20172028)
Figure 67: Market size of Tenosynovial Giant Cell Tumors (TSGCTs) by therapies in Japan, in USD Million (20172028)
Figure 68: Market Drivers
Figure 69:Market Barriers

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available